CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Noriyuki Fujii, Nobuko Matsushima, Richuan Zheng, Colleen W. Marano
Intest Res. 2021;19(4):386-397.   Published online December 1, 2020
DOI: https://doi.org/10.5217/ir.2020.00080

Excel Download

Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Intestinal Research. 2021;19(4):386-397   Crossref logo
Link1 Link2 Link3

Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies
Intestinal Research. 2017;15(4):475   Crossref logo
Link1 Link2 Link3

P406 General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies
Journal of Crohn's and Colitis. 2019;13(Supplement_1):S311-S312   Crossref logo
Link1

OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis
Journal of Crohn's and Colitis. 2022;16(Supplement_1):i037-i041   Crossref logo
Link1 Link2

OP26 Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study
Journal of Crohn's and Colitis. 2022;16(Supplement_1):i028-i029   Crossref logo
Link1 Link2

Sa1887 – General Health Status in Patients with Moderate to Severe Ulcerative Colitis Receiving Ustekinumab: Results from the Phase 3 Unifi Induction and Maintenance Studies
Gastroenterology. 2019;156(6):S-442   Crossref logo
Link1 Link2

P427 Efficacy and safety of vedolizumab and adalimumab in Asian adults with moderately to severely active ulcerative colitis: Post-hoc analysis of the VARSITY trial
Journal of Crohn's and Colitis. 2021;15(Supplement_1):S431-S432   Crossref logo
Link1 Link2

DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis
Journal of Crohn's and Colitis. 2022;16(Supplement_1):i090-i091   Crossref logo
Link1 Link2

Tu2003 Improvement in Patient-Reported Outcomes in Two Phase 3 Induction Studies of Tofacitinib in Patients With Moderately to Severely Active Ulcerative Colitis
Gastroenterology. 2016;150(4):S1003   Crossref logo
Link1 Link2

DOP71 Efficacy, safety, and tolerability of ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: Results from, UniStar, a phase 1 study
Journal of Crohn's and Colitis. 2020;14(Supplement_1):S107-S108   Crossref logo
Link1 Link2